作者: William K. Oh , Daniel J. George , Philip W. Kantoff
DOI: 10.1002/CNCR.10269
关键词:
摘要: BACKGROUND PC-SPES is an herbal supplement whose mechanisms of action are poorly understood, but may be estrogenic. The objective the current report to describe effects discontinuing PC-SPES treatment in four patients with androgen-independent prostate carcinoma. METHODS Patient charts were retrospectively reviewed. A MEDLINE search was performed investigate whether these had been previously reported. RESULTS Four men metastatic carcinoma progressed despite androgen ablation and subsequent described. All developed a rapid increase serum specific antigen (PSA) within one month stopping PC-SPES, ranging from 345% 880%. Two increased their PSA levels 1300% 1400% after 7 weeks. Compared rate rise prior during therapy, this much higher than expected. Clinical symptoms remained relatively stable serologic changes. CONCLUSIONS Discontinuing therapy can associated PSA. To authors' knowledge, effect has not reported previously. This should considered design clinical trials as well standard management patients. Cancer 2002;94:686–9. © 2002 American Society. DOI 10.1002/cncr.10269